Literature DB >> 26163224

Edaravone injection ameliorates cognitive deficits in rat model of Alzheimer's disease.

Rui Yang1, Qingjun Wang2, Fang Li3, Jian Li3, Xuewen Liu3.   

Abstract

Oxidative stress plays important role in the pathogenesis of Alzheimer's disease (AD). Edaravone is a potent free radical scavenger that exerts antioxidant effects. Therefore, in this study we aimed to investigate neuroprotective effects of edaravone for AD. Wistar rats were randomly divided into three groups (n = 15): control group, model group, and treatment group, which were injected with phosphate buffered saline, Aβ1-40, and Aβ1-40 together with 5 mg/kg edaravone, respectively, into the right hippocampal dentate gyrus. Spatial learning and memory of the rats were examined by Morris water maze test. 4-Hydroxynonenal (4-HNE) level in rat hippocampus was analyzed by immunohistochemistry. Acetylcholinesterase (AChE) and choline acetylase (ChAT) activities were assayed by commercial kits. We found that edaravone ameliorated spatial learning and memory deficits in the rats. 4-HNE level in the hippocampus as well as AChE and ChAT activities in the hippocampus was significantly lower in treatment group than in model group. In conclusion, edaravone may be developed as a novel agent for the treatment of AD for improving cholinergic system and protecting neurons from oxidative toxicity.

Entities:  

Keywords:  4-Hydroxynonenal; Alzheimer’s disease; Edaravone; Oxidative stress

Mesh:

Substances:

Year:  2015        PMID: 26163224     DOI: 10.1007/s10072-015-2314-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  20 in total

Review 1.  Modulation of oxidative stress and mitochondrial function by the ketogenic diet.

Authors:  Julie Milder; Manisha Patel
Journal:  Epilepsy Res       Date:  2011-11-09       Impact factor: 3.045

2.  Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.

Authors:  Kiyoshi Kikuchi; Ko-Ichi Kawahara; Hisaaki Uchikado; Naohisa Miyagi; Terukazu Kuramoto; Tomoya Miyagi; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Naoki Miura; Kazunori Takenouchi; Yoko Oyama; Binita Shrestha; Fumiyo Matsuda; Yoshihiro Yoshida; Shinihiro Arimura; Kentaro Mera; Ko-Ichi Tada; Narimasa Yoshinaga; Ryuichi Maenosono; Yoshiko Ohno; Teruto Hashiguchi; Ikuro Maruyama; Minoru Shigemori
Journal:  Exp Ther Med       Date:  2011-06-07       Impact factor: 2.447

3.  Oxidative damage is the earliest event in Alzheimer disease.

Authors:  A Nunomura; G Perry; G Aliev; K Hirai; A Takeda; E K Balraj; P K Jones; H Ghanbari; T Wataya; S Shimohama; S Chiba; C S Atwood; R B Petersen; M A Smith
Journal:  J Neuropathol Exp Neurol       Date:  2001-08       Impact factor: 3.685

Review 4.  A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis.

Authors:  R León; J Marco-Contelles
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 5.  Potential role of acrolein in neurodegeneration and in Alzheimer's disease.

Authors:  Thanh Nam Dang; Madeleine Arseneault; Ven Murthy; Charles Ramassamy
Journal:  Curr Mol Pharmacol       Date:  2010-06       Impact factor: 3.339

6.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

7.  Monosialoanglioside improves memory deficits and relieves oxidative stress in the hippocampus of rat model of Alzheimer's disease.

Authors:  Rui Yang; Qingjun Wang; Lianqiu Min; Rubo Sui; Jian Li; Xuewen Liu
Journal:  Neurol Sci       Date:  2012-12-11       Impact factor: 3.307

Review 8.  Rapid cognitive decline in Alzheimer's disease: a literature review.

Authors:  Alessandro Sona; Kathryn A Ellis; David Ames
Journal:  Int Rev Psychiatry       Date:  2013-12

Review 9.  The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases.

Authors:  Antonio Contestabile; Elisabetta Ciani; Andrea Contestabile
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

Review 10.  The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease.

Authors:  Kiyoshi Kikuchi; Salunya Tancharoen; Nobuyuki Takeshige; Munetake Yoshitomi; Motohiro Morioka; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2013-07-04       Impact factor: 5.923

View more
  10 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

Review 2.  Targeting Microglia in Alzheimer's Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules.

Authors:  Ziyad M Althafar
Journal:  Molecules       Date:  2022-06-27       Impact factor: 4.927

Review 3.  Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer's Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside.

Authors:  Vaibhav Walia; Deepak Kaushik; Vineet Mittal; Kuldeep Kumar; Ravinder Verma; Jatin Parashar; Rokeya Akter; Md Habibur Rahman; Saurabh Bhatia; Ahmed Al-Harrasi; Chenmala Karthika; Tanima Bhattacharya; Hitesh Chopra; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2021-11-09       Impact factor: 5.682

4.  Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats.

Authors:  Thangarajan Sumathi; Aishwariya Vedagiri; Surekha Ramachandran; Bhagyalakshmi Purushothaman
Journal:  J Mol Neurosci       Date:  2018-10-03       Impact factor: 3.444

5.  Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion.

Authors:  Tian Feng; Toru Yamashita; Ryo Sasaki; Koh Tadokoro; Namiko Matsumoto; Nozomi Hishikawa; Koji Abe
Journal:  J Cereb Blood Flow Metab       Date:  2020-10-26       Impact factor: 6.200

6.  Edaravone protects rat astrocytes from oxidative or neurotoxic inflammatory insults by restoring Akt/Bcl-2/Caspase-3 signaling axis.

Authors:  Zhe Guo; Huan-Tong Wu; Xi-Xi Li; Yun Yu; Run-Ze Gu; Rongfeng Lan; Xiao-Yan Qin
Journal:  IBRO Rep       Date:  2020-04-23

Review 7.  Microglia in Alzheimer's Disease: A Target for Therapeutic Intervention.

Authors:  Guimei Zhang; Zicheng Wang; Huiling Hu; Meng Zhao; Li Sun
Journal:  Front Cell Neurosci       Date:  2021-11-24       Impact factor: 5.505

8.  Protective Effects of Edaravone in Adult Rats with Surgery and Lipopolysaccharide Administration-Induced Cognitive Function Impairment.

Authors:  Peiqi Wang; Jiangbei Cao; Na Liu; Li Ma; Xueyue Zhou; Hong Zhang; Yongan Wang
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

9.  Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model.

Authors:  Ankit Parikh; Krishna Kathawala; Jintao Li; Chi Chen; Zhengnan Shan; Xia Cao; Yan-Jiang Wang; Sanjay Garg; Xin-Fu Zhou
Journal:  Drug Des Devel Ther       Date:  2018-07-09       Impact factor: 4.162

10.  Protective Effect of Edaravone on Cyclophosphamide Induced Oxidative Stress and Neurotoxicity in Rats.

Authors:  Sanjiv Singh; Abhishek Kumar
Journal:  Curr Drug Saf       Date:  2019
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.